Soleno Therapeutics, Inc. (SLNO) Stock Score, Valuation & Financial Research

Soleno Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SLNO

Soleno Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 53.01. These figures are a research snapshot, not a buy or sell recommendation.

What Soleno Therapeutics, Inc. does

Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Soleno Therapeutics is a biopharmaceutical company that generates revenue primarily through the commercialization and sale of its proprietary therapeutic product, VYKAT XR, in the United States. The company operates by developing novel treatments for rare diseases, managing the regulatory approval process, and executing a commercial launch strategy to sell its pharmaceutical products to healthcare providers and specialty pharmacies.

Products and services

  • The company's primary product is VYKAT XR (diazoxide choline extended-release), a therapeutic treatment for patients with Prader-Willi syndrome.

Brands and product families

  • VYKAT XR — The company's primary therapeutic product for the treatment of Prader-Willi syndrome. Source

Customer types

Healthcare providers; Specialty pharmacies.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production and supply of its drug product. Source

Business strengths to evaluate

  • Successful regulatory approval and commercial launch of VYKAT XR in the U.S. Source

Business risks and research considerations

  • Dependence on third-party manufacturers for drug supply Source
  • Risks associated with regulatory approval in international territories Source

Sources: Company research source · VYKAT XR

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SLNO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 53.01
Market capitalization:
2.76B (currency not supplied)
Revenue:
USD 285.01M
Net income:
USD 96.04M
Free cash flow:
USD 46.73M
Cash:
USD 133.03M
Total debt:
USD 4.41M
EPS:
USD 1.96
P/E ratio:
27.1x

What stands out

  • Reported year-over-year revenue growth is +49.7%.
  • Free cash flow is USD 46.73M, positive for the stored period.
  • The balance sheet shows USD 133.03M of cash versus USD 4.41M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is 16.4% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals 33.7% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 128.62M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SLNO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can SLNO sustain its current revenue growth while also converting that growth into durable profit and free cash flow?
  • Is SLNO's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
  • How is SLNO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What does the current missing revenue history warning mean for the reliability or interpretation of SLNO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research SLNO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.